LABT Overview

Lakewood-amedex Biotherapeutics Inc is a pharmaceutical company. The Company is focused on addressing unmet needs in the treatment of serious infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, NDM-1, and many others. The Company is engaged in development of its Bisphosphocin class of antimicrobial agents. The Company is exploring additional local drug delivery applications, including complicated urinary tract infections (CAUTI) and pulmonary infections. The Company has a portfolio of compounds that are being profiled for indications such as infected diabetic foot ulcer, urinary tract infections, and pulmonary infections.

Wall Street analysts forecast LABT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LABT is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lakewood-Amedex Biotherapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

Lakewood-Amedex Biotherapeutics Inc. EPS for the last quarter amounts to -0.52 USD, decreased -13.33

Lakewood-Amedex Biotherapeutics Inc (LABT) has 5 emplpoyees as of July 05 2026.

Today LABT has the market capitalization of 5.78M USD.